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Background:  Given  the  exponential  growth  in  cardiac  device  implantations,  the  need  for  less  invasive
lead  extraction  is increasing.  The  Excimer  laser  was  approved  for lead  removal  in Japan  in  2010.  The
present  study  reports  the  initial  experience  using  this  novel  technique  to  extract  chronically  implanted
pacemaker  and  implantable  cardioverter  deﬁbrillator  (ICD)  leads  from  Japanese  patients.
Methods  and  results:  We  performed  a retrospective  study  of  consecutive  patients  undergoing  lead  extrac-
tion  using  the laser  sheath  at a single  Japanese  center.  Patient  and  lead  characteristics,  indications,
and  outcomes  were  analyzed.  From  August  2010  to September  2012, a total  of 70  leads,  including  14
ICD  leads,  were  removed  using  the  laser  sheath  from  40 patients  (26 male,  14 female;  age  65.5  ±  18.3
[mean  ± SD]  years;  body  mass  index  21.8 ± 3.5 kg/m2). The  median  implant  duration  was  87 months
(range  13–328  months).  Indications  were  infection  (n =  35), venous  occlusion  (n = 4),  and  pain  (n = 1).  The
femoral  approach  was used  in  combination  with  the  laser  technique  in  ﬁve  cases.  Complete  procedural
success  was  achieved  with  68  leads  (97.1%).  Although  the  electrode  tip  was  left behind  in the  remaining
two  leads,  the desired  clinical  outcomes  could  be achieved;  which  were  deﬁned  as  clinical  success. No
cases  resulted  in failure.  There  were  no  major  complications,  including  death  and bleeding  requiring
open-chest  surgery.
Conclusions:  Laser  sheaths  appear  to provide  a feasible  and  effective  means  of extracting  chronically
d  ICD
3  Japimplanted  pacemaker  an
© 201
ntroductionThe number of implantations of cardiovascular implantable
lectronic devices (CIEDs), including permanent pacemakers
PPMs), implantable cardioverter deﬁbrillators (ICDs), and cardiac
esynchronization therapy devices (CRTs) has been increasing year
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by year [1]. As the number of patients with chronically implanted
CIEDs has grown, the number of lead-related complications requir-
ing total removal of CIED systems has been increasing [2,3]. Leads
implanted for longer than one year are likely to have adhered to
veins, myocardium, and other leads, making their removal more
difﬁcult. The Excimer laser sheath (Spectranetics, Colorado Springs,
USA) has been proven to be effective in many studies [4–7], and the
laser sheath was  approved in Japan in July 2010. Transvenous lead
extraction can be associated with serious complications [8]. We
sought to investigate the outcomes and complications associated
with the use of the laser sheath in extracting chronically implanted
PPM and ICD leads, in Japanese patients, an older and lower body
mass index (BMI) population.
vier Ltd. All rights reserved.
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ethods
tudy patients
We  performed a retrospective study of 40 consecutive patients
ndergoing lead extraction using a laser sheath at the National
erebral and Cardiovascular Center, Suita, Japan, from August 2010
o September 2012. All patients gave informed consent. The indi-
ations for transvenous lead extraction were decided based on the
eart Rhythm Society (HRS)/American Heart Association (AHA)
009 consensus document [9]. Patient characteristics, lead and
evice characteristics, indications for extraction, and outcomes
ere analyzed.
ead extraction technique
The technique of transvenous lead extraction has been reported
reviously [7]. Brieﬂy, procedures were performed in the operation
oom under general anesthesia with invasive arterial blood pres-
ure monitoring and transesophageal echocardiogram (TEE). The
atient was prepped in a manner to allow for emergent open-heart
urgery. There was cardiac surgical back up and a stand-by pump
xygenator.
Large bore sheaths were placed in the femoral artery and vein.
xtraction was performed in a stepwise approach. After a conven-
ional stylet was placed in the lead, an attempt was made to retract
he screw in active ﬁxation leads. An initial attempt was made
o remove the lead with simple traction. If manual traction was
nsuccessful, a SLS II Excimer laser sheath was introduced (Fig. 1).
To pull the lead tip with enough tension, one of two  speciﬁc
ocking stylets, Extor (VascoMed, Binzen, Germany) or LLD (Spec-
ranetics) was placed in each lead to be extracted. The SLS II laser
heath was selected from among three different sizes (12, 14, or
6 French) according to the extracting lead diameter. Fig. 2 shows
 representative lead extraction case. The SLS II laser sheath was
dvanced over the targeted lead (Fig. 2A–C) and adhesions were
ysed using the laser when required (Fig. 2D and E). The lead tip
as freed by performing “counter traction” [7], applying adequate
raction to the lead while retaining the sheath in a position close
o the atrial or ventricular endothelium (Fig. 2F) (Supplementary
ovie 1).
Supplementary data associated with this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.jjcc.2013.03.012.
ig. 1. System and device for lead extraction using laser sheath. (A) Generator of Excimer
heath  (SLS II, Spectranetics); (C) side view of laser sheath, showing the oblique shape o
heath  circumference.iology 62 (2013) 195–200
When the laser sheath alone could not be advanced due to
calciﬁed adhesions or contact between leads at a point of lead over-
lap, a mechanical polyamide sheath (VascoMed) was employed.
Also, when the subclavian approach did not work well, a femoral
approach using a GooseNeck Snare (Covidien, Plymouth, MN,  USA)
was employed.
Deﬁnition of outcome and complications
The deﬁnition of outcome has been previously reported in the
HRS/AHA 2009 consensus document [9]. Complete procedural suc-
cess was  deﬁned as the removal of all targeted leads and all lead
material from the vascular space. Even if a small portion of the lead
(e.g. the lead tip or the insulation) remained within the vascular
space, it was deﬁned as clinical success when the residual part did
not increase the risk of perforation, embolic events and perpet-
uation of infection, or cause any undesired outcome. Failure was
deﬁned as the inability to achieve either complete procedural or
clinical success, or the development of any permanently disabling
complication or procedure-related death. The deﬁnitions of major
and minor complications related to the procedure were also speci-
ﬁed according to the HRS/AHA 2009 consensus document [9]. Major
complications were deﬁned as those that were life-threatening or
that resulted in death. Other undesired events related to the pro-
cedure that required medical intervention or additional procedural
intervention were deﬁned as minor complications.
Statistics
Normally distributed continuous variables are expressed as
mean value ± standard deviation. Continuous variables that were
not normally distributed are expressed as median with range. Dis-
crete variables are shown as numbers with percentages.
Results
Patients characteristics, indications for extraction, and types of
leadsThe individual data of the 40 study patients can be found in
Table 1. Twenty-six of them were referred to us from other hospi-
tals located in the Kansai region. Patients were implanted with one
to four leads each, and a total of 70 leads were extracted using a laser
 laser (CVX-300, Spectranetics, Colorado Springs, CO, USA); (B) perspective of laser
f the tip; (D) sectional view of laser sheath, showing laser light emerging from the
H. Okamura et al. / Journal of Cardiology 62 (2013) 195–200 197
Fig. 2. Representative patient (Case 18) undergoing lead extraction. The SLS II laser sheath was advanced over the targeted lead from the subclavian vein to the heart (A–C),
with  adhesions cut using the laser when required (D and E). The lead tip was  freed by performing “counter traction” (F).
Table 1
Individual data of 40 study patients.
Case Age Sex BMI, kg/m2 Indication Device type Months after
implantation
Number of extracted
leads using laser
Lead type Result
1 40 M 24.1 Vein occlusion CRT-D 45 1 VP(DC) Complete procedural success
2  29 M 23.0 Infection CRT-P 16 1 CS(StarFix) Complete procedural success
3  37 F 22.4 Infection CRT-D 52 2 VA(DC),AA Complete procedural success
4  74 M 14.9 Infection ICD 34 2 VP(DC),AP Complete procedural success
5  73 M 13.9 Infection PM 116 2 AA,VA Complete procedural success
6  82 F 17.3 Infection PM 261 2 AP,VP Complete procedural success
7  84 F 23.6 Infection PM 142 2 VP,AA Complete procedural success
8  69 M 28.1 Infection PM 47 2 AA,VA Complete procedural success
9  87 M 18.8 Infection PM 214 2 AP,VP Complete procedural success
10  91 F 20.4 Infection PM 228 3 VP,VA,AA Complete procedural success
11  77 F 24.3 Infection PM 70 2 AP,VP Complete procedural success
12  79 M 22.6 Infection PM 119 2 AA,VA Complete procedural success
13  72 F 22.7 Infection PM 13 2 AA,VA Complete procedural success
14  37 M 27.7 Infection PM 188 2 AA,VA Complete procedural success
15  80 M 20.7 Infection ICD 47 2 VP(DC),AP Complete procedural success
16  78 M 24.0 Infection PM 222 2 AP,VP Complete procedural success
17  76 F 24.4 Infection PM 79 1 VP Complete procedural success
18  61 M 22.6 Infection ICD 136 1 VP(DC) Complete procedural success
19  76 F 25.3 Infection PM 102 2 AP,VP Complete procedural success
20  75 M 20.1 Infection PM 114 1 VP Complete procedural success
21  74 M 24.8 Infection PM 63 1 VP Complete procedural success
22  72 F 23.2 Infection PM 85 1 VP Complete procedural success
23  95 M 21.4 Infection PM 125 2 VP,AP Clinical success
24  55 M 19.1 Infection PM 249 3 VP,AP,AA Complete procedural success
25  65 M 23.3 Infection PM 153 2 AP,VP Complete procedural success
26  52 M 20.6 Vein occlusion ICD 82 1 VA(SC) Complete procedural success
27  34 M 23.5 Infection ICD 94 1 VP(DC) Complete procedural success
28  69 F 29.2 Infection PM 139 2 VP,AP Complete procedural success
29  65 M 20.0 Pain PM 58 2 VP,AA Clinical success
30  36 F 17.9 Infection ICD 99 2 VP(DC),AP Complete procedural success
31  81 F 22.0 Infection PM 328 1 VP Complete procedural success
32  78 M 22.2 Infection CRT-D 43 4 VA(DC),AP,CS,CS(StarFix) Complete procedural success
33  60 M 14.1 Infection PM 216 2 VP,AP Complete procedural success
34  80 M 18.5 Infection ICD 74 2 VA(DC),AA Complete procedural success
35  58 M 21.3 Vein occlusion ICD 77 1 VA(DC) Complete procedural success
36  35 M 22.6 Infection ICD 58 2 VA(DC),AA Complete procedural success
37  86 M 27.6 Infection PM 60 2 AA,VA Complete procedural success
38  27 F 18.4 Infection PM 68 1 VA Complete procedural success
39  69 F 21.8 Vein occlusion ICD 29 1 VA(DC) Complete procedural success
40  53 M 19.2 Infection ICD 89 1 VP(DC) Complete procedural success
AA, atrial active ﬁxation pacing lead; AP, atrial passive ﬁxation pacing lead; BMI, body mass index; CRT-D, cardiac resynchronization therapy device; CS, coronary sinus lead;
ICD,  implantable cardioverter deﬁbrillator; PM,  pacemaker; VA, ventricular active ﬁxation pacing lead; VP, ventricular passive ﬁxation pacing lead; VA(DC), ventricular active
ﬁxation  dual coil ICD lead; VA(SC), ventricular active ﬁxation single coil ICD lead; VP(DC), ventricular passive ﬁxation dual coil ICD lead; VP(SC), ventricular passive ﬁxation
single  coil ICD lead.
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Table  2
Summary data of 40 study patients.
Agea 65.5 ± 18.3
Male, n (%) 26 (65)
BMIa, kg/m2 21.8 ± 3.5
Indication for lead extraction, n (%)
Infection 35 (87.5)
Vein occlusion 4 (10)
Pain 1 (2.5)
Device type, n (%)
Pacemaker 25 (62.5)
CRT-P 1 (1.5)
ICD 11 (27.5)
CRT-D 3 (7.5)
Implant durationb, months 87 (13–328)
BMI, body mass index; CRT-D, cardiac resynchronization therapy-deﬁbrillator; CRT-
P,  cardiac resynchronization therapy-pacemaker; ICD, implantable cardioverter
deﬁbrillator.
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Table 3
Summary data of 70 extracted leads.
No. of extracted leads 70
No. of leads per patientsa 1.8 ± 0.7
Type of 70 extracted leads, n (%)
Active ﬁxation atrial lead 13 (18.6)
Passive ﬁxation atrial lead 14 (20.0)
Active ﬁxation ventricular lead 15 (21.4)
Passive ﬁxation ventricular lead 25 (35.7)
Active ﬁxation CS lead 2 (2.9)
Passive ﬁxation CS lead 1 (1.4)
Type of 14 ICD leads, n (%)
Dual coil ICD lead 13 (92.9)
F
ca Values are mean ± SD.
b Values are median (range).
heath. As shown in Table 2, the mean age was 65.5 ± 18.3 years, 26
65%) were males and 14 (35%) were females. The mean BMI  was
1.8 ± 3.5 kg/m2. The indications for lead extraction were infec-
ion (n = 35, 87.5%), venous occlusion (n = 4, 10%), and pain (n = 1,
.5%). A variety of devices were implanted, including PPMs (n = 25,
2.5%), a CRT-pacemaker (n = 1, 2.5%), ICDs (n = 11, 27.5%), and CRT-
eﬁbrillators (n = 3, 7.5%). Median implant duration was 87 months
range, 13–328 months).
The summary data of extracted leads can be seen in Table 3.
mong the 70 leads extracted via laser, the positions of the leads
ere the atrium (n = 27, 38.6%), right ventricle (n = 40, 57.1%), and
oronary sinus (CS) (n = 3, 4.3%). In terms of lead ﬁxation types,
here were 29 active ﬁxation leads (41.4%), 38 passive ﬁxation leads
54.3%), two active ﬁxation CS leads (2.9%), and one passive ﬁxation
S lead (1.4%). Of the 14 ICD leads extracted using laser, the majority
ere dual coil leads (n = 13, 92.9%), while the remaining lead was  a
ingle coil lead (7.1%).
utcomesComplete procedural success was achieved with 68 leads
97.1%). In the remaining two cases, one of which involved an atrial
assive ﬁxation lead (Case 23) and the other a ventricular passive
xation lead (Case 29), only the tip of the lead remained in the
ig. 3. Representative leads removed using the laser. (A) Case 32 with active ﬁxation IC
oronary sinus lead StarFix (Medtronic, Minneapolis, MN,  USA); (D) Case 32 with active ﬁSingle coil ICD lead 1 (7.1)
CS, coronary sinus; ICD, implantable cardioverter deﬁbrillator.
a Values are mean ± SD.
myocardium. In these cases (2.9%), there were no complications
and the desired clinical outcomes could be achieved; which were
deﬁned as clinical success. No cases resulted in failure.
In ﬁve cases, the femoral approach was  added to the subclavian
approach and the leads were removed successfully in combination
with the snare technique (Cases 15, 24, 28, 35, and 39) (Supple-
mentary Movie 2).
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.jjcc.2013.03.012.
Despite signiﬁcant adhesion of the shocking coils, all ICD leads
were successfully removed using the laser (Fig. 3A). Passive ﬁx-
ation leads were covered with more adhered tissue than active
ﬁxation leads (Fig. 3B). Active ﬁxation CS lead StarFix (Medtronic,
Minneapolis, MN,  USA) was  successfully removed in Cases 2 and 32
(Fig. 3C and D) (see “Discussion”).
In Case 3, in whom ejection fraction was  severely depressed
to ∼10% and contraction was dependent on CRT pacing, epicardial
biventricular pacing was established prior to successful lead extrac-
tion in order to keep biventricular pacing after the infected leads
were extracted. Two epicardial leads were sutured to the right and
left ventricle respectively thorough left anterolateral thoracotomy,
which enabled the epicardial leads to be isolated from infected
leads.
In Case 11, in whom extraction resulted in complete procedural
success, the moderate amount of vegetation around the tricus-
pid valve did not diminish following infected lead extraction and
adjunctive antibiotic therapy, and open-heart surgery were there-
fore required for vegetectomy.
D lead; (B) Case 9 with atrial passive ﬁxation lead; (C) Case 2 with active ﬁxation
xation coronary sinus lead StarFix with torn adjustable wings.
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tance of multiple venous approaches [10]. It is important to realize
that a laser sheath alone does not always work well, and that mas-
tering various approaches and tools will always remain useful.H. Okamura et al. / Journal 
dverse events
There were no major complications, including death, emergent
pen-chest surgery, lung embolism, or deteriorating hemodynam-
cs. A minor complication requiring blood transfusion was observed
n one case (Case 6), with unexpected bleeding from the lead inser-
ion site.
iscussion
The present study demonstrates that transvenous lead extrac-
ion using Excimer laser can be safely and effectively performed
n Japanese patients. Despite being an initial experience, the high
rocedural (97.1%) and clinical (100%) success rate and low com-
lication rate (0% major and 2.5% minor) are consistent with those
eported in other populations.
ead extraction using Excimer laser in Japanese patients
Although the SLS II laser sheath has been introduced in many
ountries, a series of the procedural results in Asia, including
apanese patients has not been reported. It is important to con-
ider the differences in physical characteristics between patients
n Western and Asian countries.
In the LExICon trial, a retrospective study using a laser sheath
ith a large number of North American patients (2405 leads from
449 patients), approximately two-thirds of the patients had a
MI  ≥ 25 kg/m2 [6]. Importantly, the LExICon trial demonstrated
hat a BMI  < 25 kg/m2 was associated with an increased risk of pro-
edural major adverse events (MAEs). It also demonstrated that a
onger duration of lead implantation was associated with a higher
isk of procedural failure [6]. The present study found a low mean
MI  value of 21.8 kg/m2. The median duration of lead implanta-
ion was 87 months, which was comparable to the 82 months
bserved in the LExICon trial. Based on the LExICon trial data,
atients in the present study, including many low BMI patients
nd leads implanted for many years, appeared to be at high risk for
rocedure-related MAEs. However, as shown in Table 1, the suc-
ess rate of complete removal was high, at 97.1%, without major
omplications.
Comparing the indications for lead extraction, infection was  the
ajor cause in both the present and previous studies [4–7,10].
owever, there were no extractions for lead failure in the
resent study. This may  represent a bias to remove only leads
hat must be removed early in our extraction experience. The
ExICon trial reported an increased all-cause, in-hospital mor-
ality in infected patients (3% vs. 0.3%, p < 0.0001, odds ratio:
.7) [6]. There were no in-hospital deaths observed in the
resent study, despite a higher rate of infected leads in this
tudy (87.5%) vs. approximately 60% in the previous studies that
ncluded more patients with nonfunctional or abandoned leads
4–7,10].
In the present study, there were no MAEs such as superior vena
ava tears, cardiac tamponade, or massive pulmonary embolism. It
as reported that deaths and life-threatening injuries associated
ith transvenous lead extraction were caused primarily by lacer-
tions of the right atrium, superior vena cava, or innominate vein
8]. As part of our preparation for beginning a lead extraction pro-
ram, we ensured all the personnel and equipment, as outlined in
he consensus document were ready and available. This included
he ability to perform emergent, on pump, open heart surgery [9].
oreover, in addition to preoperative meetings, we followed the
tepwise approach starting from a smaller size laser sheath chang-
ng to a larger one in combination with mechanical sheath and
ounter-traction technique.iology 62 (2013) 195–200 199
Technical improvements in the present study
In this study we tried to remove six CS leads. Three (50%) CS leads
were removed with manual traction, whereas the remaining three
required laser extraction. There have been several reports on the
extraction of CS leads [11–13]. It was reported that most chronically
implanted CS leads could be removed by manual traction; however,
30% in one study or 12.5% in another study of the leads required
mechanical dilatation or a laser sheath [11,12]. The high percentage
of laser utilization in the present study seemed to be related to the
StarFix active ﬁxation CS lead. Fig. 4 shows the setup of StarFix. It is
designed to extend its adjustable wings so that it can be ﬁxed within
the thick branch of the coronary sinus [13]. Each of the two cases
we experienced with the StarFix lead required laser extraction. Our
experience was similar to the prior report of four cases with StarFix,
which required the laser sheath in all cases [14]. It is supposed that
the risk of adverse events caused by extracting adhered CS leads
exceeds that of typical atrial or ventricular leads. Risk assessment
for types of CS leads is required.
In this study, the subclavian approach worked well in most
cases (35 of 40 patients). However, a mechanical sheath was fre-
quently required, and the femoral approach with snare technique
was added in ﬁve cases (12.5%). Bongiorni et al. indicated the impor-Fig. 4. Setup and characteristics of StarFix lead (Medtronic, Minneapolis, MN,  USA).
The StarFix lead is designed to extend adjustable wings so that it can be ﬁxed within
the thick branch of the coronary sinus.
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tudy limitations
This study was a single-center, single-operator experience in
apan, and the number of the cases was limited. Indeed, the total
umber of patients who underwent lead extraction using laser all
ver Japan during this study period was almost tenfold greater than
ur study population. We  need to examine the safety and efﬁcacy
f laser sheaths in Japanese patients in a larger multicenter study.
onclusions
In the initial experience of 40 consecutive patients, the Excimer
aser appeared to be safe and effective for extracting chronically
mplanted pacemaker and ICD leads in Japanese patients.
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eferences
[1] Kurtz SM,  Ochoa JA, Lau E, Shkolnikov Y, Pavri BB, Frisch D, Greenspon AJ.
Implantation trends and patient proﬁles for pacemakers and implantable car-
dioverter deﬁbrillators in the United States. PACE 2010;33:705–11.
[2] Greenspon AJ, Patel JD, Lau E, Ochoa JA, Frisch DR, Ho RT, Pavri BB, Kurtz
SM. 16-Year trends in the infection burden for pacemakers and implantable
cardioverter-deﬁbrillators in the United States 1993 to 2008. J Am Coll Cardiol
2011;58:1001–6.
[3] Osmonov D, Ozcan KS, Erdinler I, Altay S, Yildirim E, Turkkan C, Ekmekci A,
Gungor B, Gurkan K. Cardiac device-related endocarditis: 31-years’ experience.
J  Cardiol 2013;61:175–80.
[4] Wilkoff BL, Byrd CL, Love CJ, Hayes DL, Sellers TD, Schaerf R, Parsonnet V, Epstein
LM,  Sorrentino RA, Reiser C. Pacemaker lead extraction with the laser sheath:
results of pacing lead extraction with the excimer sheath (PLEXES) trial. J Am
Coll Cardiol 1999;33:1671–6.
[iology 62 (2013) 195–200
[5] Jones SO, Eckart RE, Albert CM,  Epstein LM.  Large, single-center, single operator
experience with transvenous lead extraction: outcomes and changing indica-
tions. Heart Rhythm 2008;5:520–5.
[6] Wazni O, Epstein LM,  Carrillo RG, Love C, Adler SW,  Riggio DW,  Karin SS, Bashir
J,  Greenspon AJ, DiMarco JP, Cooper JM,  Onufer JR, Ellenbogen KA, Kutalek SP,
Dentry MS, et al. Lead extraction in the contemporary setting: the LExICon
study. J Am Coll Cardiol 2011;55:579–86.
[7] Kennergren C, Bucknall CA, Butter C, Charles R, Fuhrer J, Grosfeld M, Tav-
ernier R, Morgado TB, Mortensen P, Paul V, Richter P, Schwartz T, Wellens
F.  Laser-assisted lead extraction: the European experience. Europace 2007;9:
651–6.
[8] Hauser RG, Katsiyiannis WT,  Gornick CC, Almquist AK, Kallinen LM.
Deaths and cardiovascular injuries due to device-assisted implantable
cardioverter-deﬁbrillator and pacemaker lead extraction. Europace 2010;12:
395–401.
[9] Wilkoff BL, Love CJ, Byrd CL, Bongiorni MG,  Carrillo RG, Crossley GH,  Epstein LM,
Friedman RA, Kennergren CE, Mitkowski P, Schaerf RH, Wazni OM.  Transvenous
lead extraction: Heart Rhythm Society expert consensus on facilities, train-
ing,  indications, and patient management: this document was endorsed by the
American Heart Association (AHA). Heart Rhythm 2009;6:1085–104.
10] Bongiorni MG,  Soldati E, Zucchelli G, Cori AD, Segreti L, Lucia RD, Solarino G, Bal-
barini A, Marzilli M,  Mariani M.  Transvenous removal of pacing and implantable
cardiac deﬁbrillating leads using single sheath mechanical dilatation and mul-
tiple venous approaches: high success rate and safety in more than 2000 leads.
Eur Heart J 2008;29:2886–93.
11] Coli AD, Bongiorni MG,  Zucchelli G, Segreti L, Viani S, Lucia RD, Paperini L,
Soldati E. Large, single-center experience in transvenous coronary sinus lead
extraction: procedural outcome and predictors for mechanical dilation. PACE
2012;35:215–22.
12] Hamid S, Arujna A, Khan S, Ladwiniec A, McPhail M,  Bostock J, Mobb M, Patel
N,  Bucknall C, Rinaldi CA. Extraction of chronic pacemaker and deﬁbrillator
lead from the coronary sinus: laser infrequently used but required. Europace
2009;11:213–5.
13] Nagai T, Okayama H, Nishimura K, Inoue K, Suzuki J, Ogimoto A, Ohtsuka T,
Hiasa G, Sumimoto T, Funada J, Higaki J. Initial Japanese experience and long-
term  follow-up with a new active ﬁxation coronary sinus lead, the StarFix 4195.
JC  Case 2010;1:e176–9.
14] Cronin EM,  Ingelmo CP, Rickard J, Wazni OM,  Martin DO, Wilkoff BL, Baranowski
B. Active ﬁxation mechanism complicates coronary sinus lead extraction
and limits subsequent reimplantation targets. J Interv Card Electrophysiol
2013;36:81–6.
